Glenmark Expands Injectable Portfolio with Acetylcysteine Acquisition

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296), has acquired and launched Acetylcysteine Injection, 6 g/30 mL (200 mg/mL). This marks Glenmark's eighth commercial product in its injectable portfolio for the US market. The acquisition, completed in Q2 FY25, strengthens the company's presence in the institutional channel. Acetylcysteine Injection is used to treat acetaminophen overdose and as a mucolytic agent. This strategic move aligns with Glenmark's commitment to expanding its product offerings and providing affordable alternatives to patients. The company's shares closed at ₹1,278.75 on February 28, 2025, reflecting investor confidence in its growth strategy.